Butylphthalide

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Butylphthalide
Accession Number
DB12749
Type
Small Molecule
Groups
Investigational
Description

Butylphthalide has been used in trials studying the prevention of Restenosis.

Structure
Thumb
Synonyms
  • 3-n-butylphthalide
Categories
UNII
822Q956KGM
CAS number
6066-49-5
Weight
Average: 190.2384
Monoisotopic: 190.099379692
Chemical Formula
C12H14O2
InChI Key
HJXMNVQARNZTEE-UHFFFAOYSA-N
InChI
InChI=1S/C12H14O2/c1-2-3-8-11-9-6-4-5-7-10(9)12(13)14-11/h4-7,11H,2-3,8H2,1H3
IUPAC Name
3-butyl-1,3-dihydro-2-benzofuran-1-one
SMILES
CCCCC1OC(=O)C2=C1C=CC=C2

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
AbciximabButylphthalide may increase the anticoagulant activities of Abciximab.Approved
AcenocoumarolButylphthalide may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Butylphthalide is combined with Acetylsalicylic acid.Approved, Vet Approved
AloxiprinThe risk or severity of adverse effects can be increased when Butylphthalide is combined with Aloxiprin.Experimental
AlprostadilAlprostadil may increase the antiplatelet activities of Butylphthalide.Approved, Investigational
AlteplaseButylphthalide may increase the anticoagulant activities of Alteplase.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Butylphthalide is combined with Aminosalicylic Acid.Approved
AnagrelideButylphthalide may increase the anticoagulant activities of Anagrelide.Approved
AncrodButylphthalide may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideAndrographolide may increase the antiplatelet activities of Butylphthalide.Investigational
AnistreplaseButylphthalide may increase the anticoagulant activities of Anistreplase.Approved
Antithrombin III humanButylphthalide may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanThe risk or severity of adverse effects can be increased when Butylphthalide is combined with Apixaban.Approved
ArdeparinButylphthalide may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanButylphthalide may increase the anticoagulant activities of Argatroban.Approved, Investigational
AstaxanthinButylphthalide may increase the anticoagulant activities of Astaxanthin.Investigational
AzelastineAzelastine may increase the antiplatelet activities of Butylphthalide.Approved
BalsalazideThe risk or severity of adverse effects can be increased when Butylphthalide is combined with Balsalazide.Approved, Investigational
BatroxobinButylphthalide may increase the anticoagulant activities of Batroxobin.Experimental
BecaplerminButylphthalide may increase the anticoagulant activities of Becaplermin.Approved, Investigational
BemiparinButylphthalide may increase the anticoagulant activities of Bemiparin.Approved, Investigational
BeraprostButylphthalide may increase the anticoagulant activities of Beraprost.Investigational
BivalirudinButylphthalide may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BrinaseButylphthalide may increase the anticoagulant activities of Brinase.Experimental
BuflomedilButylphthalide may increase the antiplatelet activities of Buflomedil.Experimental
CangrelorButylphthalide may increase the anticoagulant activities of Cangrelor.Approved
CaplacizumabButylphthalide may increase the anticoagulant activities of Caplacizumab.Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Butylphthalide is combined with Carbaspirin calcium.Experimental, Investigational
CertoparinButylphthalide may increase the anticoagulant activities of Certoparin.Approved, Investigational
CilostazolButylphthalide may increase the anticoagulant activities of Cilostazol.Approved, Investigational
Citric AcidButylphthalide may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClopidogrelButylphthalide may increase the anticoagulant activities of Clopidogrel.Approved
CloricromenButylphthalide may increase the anticoagulant activities of Cloricromen.Experimental
ClorindioneButylphthalide may increase the anticoagulant activities of Clorindione.Experimental
Collagenase clostridium histolyticumThe risk or severity of adverse effects can be increased when Butylphthalide is combined with Collagenase clostridium histolyticum.Approved, Investigational
Dabigatran etexilateButylphthalide may increase the anticoagulant activities of Dabigatran etexilate.Approved
DalteparinButylphthalide may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidButylphthalide may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanButylphthalide may increase the anticoagulant activities of Darexaban.Investigational
DasatinibDasatinib may increase the anticoagulant activities of Butylphthalide.Approved, Investigational
DefibrotideButylphthalide may increase the anticoagulant activities of Defibrotide.Approved, Investigational
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Butylphthalide is combined with Deoxycholic Acid.Approved
DersalazineThe risk or severity of adverse effects can be increased when Butylphthalide is combined with Dersalazine.Investigational
DesirudinButylphthalide may increase the anticoagulant activities of Desirudin.Approved
DesmoteplaseButylphthalide may increase the anticoagulant activities of Desmoteplase.Investigational
DextranButylphthalide may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DicoumarolButylphthalide may increase the anticoagulant activities of Dicoumarol.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Butylphthalide is combined with Diflunisal.Approved, Investigational
DiphenadioneButylphthalide may increase the anticoagulant activities of Diphenadione.Experimental
DipyridamoleButylphthalide may increase the anticoagulant activities of Dipyridamole.Approved
DitazoleButylphthalide may increase the anticoagulant activities of Ditazole.Approved, Withdrawn
Drotrecogin alfaButylphthalide may increase the anticoagulant activities of Drotrecogin alfa.Approved, Investigational, Withdrawn
Edetic AcidButylphthalide may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanButylphthalide may increase the anticoagulant activities of Edoxaban.Approved
EnoxaparinButylphthalide may increase the anticoagulant activities of Enoxaparin.Approved
EpinastineEpinastine may increase the antiplatelet activities of Butylphthalide.Approved, Investigational
EplivanserinButylphthalide may increase the anticoagulant activities of Eplivanserin.Investigational
eplivanserineButylphthalide may increase the anticoagulant activities of eplivanserine.Investigational
EpoprostenolButylphthalide may increase the anticoagulant activities of Epoprostenol.Approved
EptifibatideButylphthalide may increase the anticoagulant activities of Eptifibatide.Approved, Investigational
Ethyl biscoumacetateButylphthalide may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Ferulic acidButylphthalide may increase the anticoagulant activities of Ferulic acid.Experimental
FibrinolysinButylphthalide may increase the anticoagulant activities of Fibrinolysin.Investigational
FluindioneButylphthalide may increase the anticoagulant activities of Fluindione.Approved, Investigational
FondaparinuxButylphthalide may increase the anticoagulant activities of Fondaparinux.Approved, Investigational
Fondaparinux sodiumButylphthalide may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
GabexateButylphthalide may increase the anticoagulant activities of Gabexate.Investigational
GlucosamineGlucosamine may increase the antiplatelet activities of Butylphthalide.Approved, Investigational
GuacetisalThe risk or severity of adverse effects can be increased when Butylphthalide is combined with Guacetisal.Experimental
Hemoglobin crosfumarilThe risk or severity of adverse effects can be increased when Butylphthalide is combined with Hemoglobin crosfumaril.Experimental
HeparinButylphthalide may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineButylphthalide may increase the anticoagulant activities of Higenamine.Investigational
HydroxytyrosolButylphthalide may increase the antiplatelet activities of Hydroxytyrosol.Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Butylphthalide is combined with Ibritumomab tiuxetan.Approved, Investigational
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Butylphthalide.Approved
IbudilastIbudilast may increase the antiplatelet activities of Butylphthalide.Approved, Investigational
Icosapent ethylIcosapent ethyl may increase the antiplatelet activities of Butylphthalide.Approved, Investigational, Nutraceutical
IdraparinuxButylphthalide may increase the anticoagulant activities of Idraparinux.Investigational
IfenprodilIfenprodil may increase the antiplatelet activities of Butylphthalide.Approved, Investigational, Withdrawn
IfetrobanIfetroban may increase the antiplatelet activities of Butylphthalide.Investigational
IloprostButylphthalide may increase the anticoagulant activities of Iloprost.Approved, Investigational
IndobufenButylphthalide may increase the anticoagulant activities of Indobufen.Investigational
KetanserinKetanserin may increase the antiplatelet activities of Butylphthalide.Investigational
LepirudinButylphthalide may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanButylphthalide may increase the anticoagulant activities of Letaxaban.Investigational
LimaprostLimaprost may increase the antiplatelet activities of Butylphthalide.Approved, Investigational
LinsidomineButylphthalide may increase the antiplatelet activities of Linsidomine.Experimental
MelagatranButylphthalide may increase the anticoagulant activities of Melagatran.Experimental
MesalazineThe risk or severity of adverse effects can be increased when Butylphthalide is combined with Mesalazine.Approved
Methyl salicylateThe risk or severity of adverse effects can be increased when Butylphthalide is combined with Methyl salicylate.Approved, Vet Approved
MilrinoneMilrinone may increase the antiplatelet activities of Butylphthalide.Approved
NadroparinButylphthalide may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatButylphthalide may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftopidilNaftopidil may increase the antiplatelet activities of Butylphthalide.Investigational
NimesulideNimesulide may increase the antiplatelet activities of Butylphthalide.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Butylphthalide is combined with Nitroaspirin.Investigational
ObinutuzumabThe risk or severity of adverse effects can be increased when Butylphthalide is combined with Obinutuzumab.Approved, Investigational
OlsalazineThe risk or severity of adverse effects can be increased when Butylphthalide is combined with Olsalazine.Approved
Omega-3 fatty acidsOmega-3 fatty acids may increase the antiplatelet activities of Butylphthalide.Approved, Nutraceutical
OtamixabanButylphthalide may increase the anticoagulant activities of Otamixaban.Investigational
OzagrelButylphthalide may increase the anticoagulant activities of Ozagrel.Investigational
ParnaparinButylphthalide may increase the anticoagulant activities of Parnaparin.Approved, Investigational
Pentaerythritol TetranitrateButylphthalide may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Butylphthalide.Approved
PentoxifyllinePentoxifylline may increase the antiplatelet activities of Butylphthalide.Approved, Investigational
PhenindioneButylphthalide may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonButylphthalide may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
Phenyl aminosalicylateThe risk or severity of adverse effects can be increased when Butylphthalide is combined with Phenyl aminosalicylate.Approved
PicotamideButylphthalide may increase the anticoagulant activities of Picotamide.Experimental
PrasugrelButylphthalide may increase the anticoagulant activities of Prasugrel.Approved
Protein CButylphthalide may increase the anticoagulant activities of Protein C.Approved
Protein S humanButylphthalide may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeButylphthalide may increase the anticoagulant activities of Protocatechualdehyde.Approved
RamatrobanButylphthalide may increase the antiplatelet activities of Ramatroban.Investigational
RelcovaptanButylphthalide may increase the antiplatelet activities of Relcovaptan.Investigational
ResveratrolResveratrol may increase the antiplatelet activities of Butylphthalide.Approved, Experimental, Investigational
ReteplaseButylphthalide may increase the anticoagulant activities of Reteplase.Approved, Investigational
ReviparinButylphthalide may increase the anticoagulant activities of Reviparin.Approved, Investigational
RidogrelRidogrel may increase the antiplatelet activities of Butylphthalide.Approved
RivaroxabanButylphthalide may increase the anticoagulant activities of Rivaroxaban.Approved
RosiglitazoneButylphthalide may increase the anticoagulant activities of Rosiglitazone.Approved, Investigational
Salicylic acidThe risk or severity of adverse effects can be increased when Butylphthalide is combined with Salicylic acid.Approved, Investigational, Vet Approved
SarpogrelateButylphthalide may increase the anticoagulant activities of Sarpogrelate.Investigational
SaruplaseButylphthalide may increase the anticoagulant activities of Saruplase.Experimental
SelexipagButylphthalide may increase the anticoagulant activities of Selexipag.Approved
SevofluraneSevoflurane may increase the antiplatelet activities of Butylphthalide.Approved, Vet Approved
SRT501SRT501 may increase the antiplatelet activities of Butylphthalide.Investigational
StreptokinaseButylphthalide may increase the anticoagulant activities of Streptokinase.Approved, Investigational
SulodexideButylphthalide may increase the anticoagulant activities of Sulodexide.Approved, Investigational
TenecteplaseButylphthalide may increase the anticoagulant activities of Tenecteplase.Approved
TesmilifeneTesmilifene may increase the antiplatelet activities of Butylphthalide.Investigational
TicagrelorButylphthalide may increase the anticoagulant activities of Ticagrelor.Approved
TiclopidineButylphthalide may increase the anticoagulant activities of Ticlopidine.Approved
TinzaparinButylphthalide may increase the anticoagulant activities of Tinzaparin.Approved
TioclomarolButylphthalide may increase the anticoagulant activities of Tioclomarol.Experimental
TipranavirTipranavir may increase the antiplatelet activities of Butylphthalide.Approved, Investigational
TirofibanButylphthalide may increase the anticoagulant activities of Tirofiban.Approved
TositumomabThe risk or severity of adverse effects can be increased when Butylphthalide is combined with Tositumomab.Approved, Investigational
TranilastTranilast may increase the antiplatelet activities of Butylphthalide.Approved, Investigational
TrapidilTrapidil may increase the antiplatelet activities of Butylphthalide.Approved
TreprostinilButylphthalide may increase the anticoagulant activities of Treprostinil.Approved, Investigational
TriflusalButylphthalide may increase the anticoagulant activities of Triflusal.Approved, Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Butylphthalide is combined with Trolamine salicylate.Approved
TroxerutinButylphthalide may increase the anticoagulant activities of Troxerutin.Investigational
UrokinaseButylphthalide may increase the anticoagulant activities of Urokinase.Approved, Investigational, Withdrawn
Vitamin EVitamin E may increase the antiplatelet activities of Butylphthalide.Approved, Nutraceutical, Vet Approved
VorapaxarButylphthalide may increase the anticoagulant activities of Vorapaxar.Approved
WarfarinButylphthalide may increase the anticoagulant activities of Warfarin.Approved
XimelagatranButylphthalide may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0032064
PubChem Compound
61361
PubChem Substance
347828938
ChemSpider
55293
ChEMBL
CHEMBL248594
Wikipedia
Butylphthalide

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3CompletedPreventionRestenosis1
4RecruitingTreatmentAcute Ischemic Stroke (AIS)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0654 mg/mLALOGPS
logP3ALOGPS
logP3.36ChemAxon
logS-3.5ALOGPS
pKa (Strongest Acidic)15.7ChemAxon
pKa (Strongest Basic)-6.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count1ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area26.3 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity54.78 m3·mol-1ChemAxon
Polarizability21.29 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as benzofuranones. These are organic compounds containing a benzene ring fused to a furanone.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzofurans
Sub Class
Benzofuranones
Direct Parent
Benzofuranones
Alternative Parents
Phthalides / Benzenoids / Lactones / Carboxylic acid esters / Oxacyclic compounds / Monocarboxylic acids and derivatives / Organooxygen compounds / Organic oxides / Hydrocarbon derivatives
Substituents
Isobenzofuranone / Phthalide / Benzofuranone / Isocoumaran / Benzenoid / Lactone / Carboxylic acid ester / Oxacycle / Monocarboxylic acid or derivatives / Carboxylic acid derivative
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on October 20, 2016 18:01 / Updated on May 02, 2018 00:24